Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula 1



or a pharmaceutically acceptable salt[[,]] or solvate, ~~clathrate, or prodrug~~ thereof, wherein:

R_1 is H or methyl;

each of R_2 and R_3 is independently H, halogen, $(C_1\text{-}C_3)$alkyl, or $(C_1\text{-}C_3)$alkoxy; or R_2 and R_3 taken together form an optionally substituted methylidene selected from the group consisting of ~~or a 3- to 7-membered ring optionally comprising 0-3 heteroatoms~~;



1a



1b



1c



1d



1e



1f



1g



1h



1i 1j 1k 1l



1m 1n

wherein:

n is an integer of 0-3;

each R_7 is independently H, alkyl, carboxylic acid, amine, halogen, nitro, cyano, X_1, X_2-(C-C_4)alkyl-R_8, X_2-(C_1-C_4)alkenyl-R_8, or X_2-(C_1-C_4)alkynyl-R_8;

X_1 is -C(O)NR_9-, -NR_9C(O)-, -C(O)O-, C(O)R_{11}, -OC(O)-, -O-, -NR_9-, -S-, -S(O_2), or -S(O_2)NR_9-;

X_2 is a chemical bond, -C(O)NR_9-, -NR_9C(O)-, -C(O)O-, C(O)R_{11}, -OC(O)-, -O-, -NR_9-, -S-, -S(O_2), or -S(O_2)NR_9-;

R_8 is selected from the group consisting of hydrogen, dialkylamino, carboxyl, hydoxyl, alkoxy, sulfonamide, urea, carbamate, diol, alkylsulphonyl, and R_{10};

R_9 is H or (C_1-C_3)alkyl;

R_{10} is an optionally substituted 5- or 6-membered saturated, unsaturated, or aromatic heterocycle comprising from 1 to 4 heteroatoms; and

R_{11}, is an optionally substituted 5- to 6-membered saturated heterocyclic ring;

R_4 is H, methyl, trifluoromethyl, (C_1-C_4)alkyl, alkoxy, amido, amino, or optionally substituted aryl;

X is a chemical bond, ethynyl, -O-, -S-, -S(O)-, -$S(O_2)$-, -$NR_5C(O)$-, or - NR_5-, wherein R_5 is H, methyl, or substituted methylene;

Y is a 5- to 10-membered mono or bicyclic, saturated, unsaturated, or aromatic ring comprising 0-3 heteroatoms and optionally substituted; and

Z is CR_6, wherein R_6 is H, halogen, nitro, cyano, alkoxyl, sulfonamide, amino, or amide.

2. (Original) The compound of claim 1 wherein X is a chemical bond, -O-, -S-, or - NR_5-.

3. (Currently Amended) The compound of claim 1 wherein Y is selected from the group consisting of phenyl, indolyl, indolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl, benzotriazolyl, pyridyl, pyrimidyl, 4-substituted piperazin-1-yl, morpholino, piperidinyl, pyrrolidin-1-yl, furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridopyrrolyl, pyridazopyrrolyl, pyrimidopyrrolyl, pyrazopyrrolyl, and pyridofuranyl~~, and derivatives thereof~~.

4. (Canceled)

5. (Original) The compound of claim 1 wherein R_2 and R_3 are both H, halogen, or methyl.

6. (Original) The compound of claim 1 wherein R_2 and R_3 are taken together to form a ring selected from the group consisting of 1,3-dioxolane, 1,3-dioxane, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

7. (Canceled)

8. (Currently Amended) The compound of claim [[7]] 1 wherein R_7 is X_2-(C_1-C_4)alkyl-R_8, X_2-(C_1-C_4)alkenyl-R_8, or X_2-(C_1-C_4)alkynyl-R_8, and R_8 is selected from the group consisting of alkylsulfonyl, alkoxy, carboxyl, morpholino, 1-alkyl-piperazin-4-yl, pyrrolidinyl, piperidinyl, pyridyl, imidazolo, triazolo, tetrazolo, and thiazolo.

9. (Original) The compound of claim 1 wherein R_4 is H, methyl, or trifluoromethyl.

10. (Currently Amended) The compound of claim 1 wherein ~~if Z is CH,~~ R_1 is CH_3 or R_3 and R_2 do not form an optionally substituted methylindene.

11. (Currently Amended) A compound selected from the group consisting of:



,



,



, and



,

and pharmaceutically acceptable salts[[,]] or solvates, ~~clathrates, and prodrugs~~ thereof.

Claims 12 – 21 (Canceled)

22. (Currently Amended) A pharmaceutical composition comprising a compound of ~~Formula 1~~claim 1, or a pharmaceutically acceptable salt[[,]] or solvate, ~~clathrate, or prodrug~~ thereof, and a pharmaceutically acceptable carrier.

23. (Original) The pharmaceutical composition comprising a compound of claim 11 and a pharmaceutical acceptable carrier or excipient.

24. (Original) The pharmaceutical composition of claim 22 which is suitable for oral, transdermal, topical, parenteral, or mucosal administration.

25 – 35. (Canceled)